Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai
ABSTRACT: Background: Dubai Health Authority currently recommends sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent pneumococcal disease among adults at elevated risk of illness. Despite rec...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Current Therapeutic Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0011393X23000085 |
| _version_ | 1827920712738799616 |
|---|---|
| author | Mostafa Zayed, MSc Jean Joury, BS Pharm, CMD Mohamed Farghaly, FRCGP Sara Al Dallal, MD, MSc Bassam Mahboub, MD Emily Kutrieb, BA Ahuva Averin, MPP |
| author_facet | Mostafa Zayed, MSc Jean Joury, BS Pharm, CMD Mohamed Farghaly, FRCGP Sara Al Dallal, MD, MSc Bassam Mahboub, MD Emily Kutrieb, BA Ahuva Averin, MPP |
| author_sort | Mostafa Zayed, MSc |
| collection | DOAJ |
| description | ABSTRACT: Background: Dubai Health Authority currently recommends sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent pneumococcal disease among adults at elevated risk of illness. Despite recommendations, disease burden and associated costs remain substantial. A new 20-valent pneumococcal conjugate vaccine (PCV20) recently received regulatory approval in the United Arab Emirates and has the potential to further reduce burden of pneumococcal disease. Objectives: To evaluate budget impact of use of novel PCV20 compared with current recommendations (ie, PCV13→PPV23) among expatriates in Dubai aged 50 to 99 years and those aged 19 to 49 years with risk factors. Methods: A deterministic model depicted 5-year risks and costs of invasive pneumococcal disease and all-cause nonbacteremic pneumonia. Each year of the modeling horizon, persons could be vaccinated with either PCV20 or PCV13→PPV23 or remain unvaccinated; persons vaccinated during the modeling horizon were not eligible for vaccination in subsequent years. Annual vaccine uptake was assumed to be 5% in base cases analyses; higher uptake was considered in scenario analyses. Costs were discounted at 3.5% annually and reported in US dollars. Results: In base case, use of PCV20 alone would prevent an additional 13 cases of invasive pneumococcal disease, 31 cases of inpatient all-cause nonbacteremic pneumonia, 139 cases of outpatient all-cause nonbacteremic pneumonia, and 5 disease-related deaths compared with PCV13→PPV23. Medical care costs would be reduced by $354,000, and total vaccination costs would decrease by $4.4 million. PCV20 would therefore yield net budgetary impact of –$4.8 million, resulting in savings of $2.47 per-person per-year over 5 years. In scenarios with higher vaccine uptake, PCV20 prevented more cases and deaths and yielded greater budget savings (vs PCV13→PPV23). Conclusions: PCV20 would reduce burden and economic costs of pneumococcal disease among expatriates in Dubai compared with PCV13→PPV23 and would therefore be budget saving for private health insurers who cover the majority of this population. |
| first_indexed | 2024-03-13T04:14:48Z |
| format | Article |
| id | doaj.art-99b16be1e4ac4d40ab5b25668a19bf80 |
| institution | Directory Open Access Journal |
| issn | 0011-393X |
| language | English |
| last_indexed | 2024-03-13T04:14:48Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Therapeutic Research |
| spelling | doaj.art-99b16be1e4ac4d40ab5b25668a19bf802023-06-21T06:50:45ZengElsevierCurrent Therapeutic Research0011-393X2023-01-0198100698Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in DubaiMostafa Zayed, MSc0Jean Joury, BS Pharm, CMD1Mohamed Farghaly, FRCGP2Sara Al Dallal, MD, MSc3Bassam Mahboub, MD4Emily Kutrieb, BA5Ahuva Averin, MPP6Pfizer Gulf FZ LLC, Dubai, United Arab EmiratesPfizer Gulf FZ LLC, Dubai, United Arab EmiratesDubai Health Authority, Dubai, United Arab EmiratesDubai Health Authority, Dubai, United Arab EmiratesDubai Health Authority, Dubai, United Arab EmiratesPolicy Analysis Inc, Boston, MassachusettsPolicy Analysis Inc, Boston, Massachusetts; Address correspondence to: Ahuva Averin, MPP, Policy Analysis Inc, 116 Huntington Ave, Suite 903, Boston, MA 02116ABSTRACT: Background: Dubai Health Authority currently recommends sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent pneumococcal disease among adults at elevated risk of illness. Despite recommendations, disease burden and associated costs remain substantial. A new 20-valent pneumococcal conjugate vaccine (PCV20) recently received regulatory approval in the United Arab Emirates and has the potential to further reduce burden of pneumococcal disease. Objectives: To evaluate budget impact of use of novel PCV20 compared with current recommendations (ie, PCV13→PPV23) among expatriates in Dubai aged 50 to 99 years and those aged 19 to 49 years with risk factors. Methods: A deterministic model depicted 5-year risks and costs of invasive pneumococcal disease and all-cause nonbacteremic pneumonia. Each year of the modeling horizon, persons could be vaccinated with either PCV20 or PCV13→PPV23 or remain unvaccinated; persons vaccinated during the modeling horizon were not eligible for vaccination in subsequent years. Annual vaccine uptake was assumed to be 5% in base cases analyses; higher uptake was considered in scenario analyses. Costs were discounted at 3.5% annually and reported in US dollars. Results: In base case, use of PCV20 alone would prevent an additional 13 cases of invasive pneumococcal disease, 31 cases of inpatient all-cause nonbacteremic pneumonia, 139 cases of outpatient all-cause nonbacteremic pneumonia, and 5 disease-related deaths compared with PCV13→PPV23. Medical care costs would be reduced by $354,000, and total vaccination costs would decrease by $4.4 million. PCV20 would therefore yield net budgetary impact of –$4.8 million, resulting in savings of $2.47 per-person per-year over 5 years. In scenarios with higher vaccine uptake, PCV20 prevented more cases and deaths and yielded greater budget savings (vs PCV13→PPV23). Conclusions: PCV20 would reduce burden and economic costs of pneumococcal disease among expatriates in Dubai compared with PCV13→PPV23 and would therefore be budget saving for private health insurers who cover the majority of this population.http://www.sciencedirect.com/science/article/pii/S0011393X23000085Budgetary impactImmunizationPublic healthStreptococcus pneumoniaeVaccination |
| spellingShingle | Mostafa Zayed, MSc Jean Joury, BS Pharm, CMD Mohamed Farghaly, FRCGP Sara Al Dallal, MD, MSc Bassam Mahboub, MD Emily Kutrieb, BA Ahuva Averin, MPP Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai Current Therapeutic Research Budgetary impact Immunization Public health Streptococcus pneumoniae Vaccination |
| title | Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai |
| title_full | Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai |
| title_fullStr | Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai |
| title_full_unstemmed | Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai |
| title_short | Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai |
| title_sort | budgetary impact of 20 valent pneumococcal conjugate vaccine use for adult expatriates living in dubai |
| topic | Budgetary impact Immunization Public health Streptococcus pneumoniae Vaccination |
| url | http://www.sciencedirect.com/science/article/pii/S0011393X23000085 |
| work_keys_str_mv | AT mostafazayedmsc budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT jeanjourybspharmcmd budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT mohamedfarghalyfrcgp budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT saraaldallalmdmsc budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT bassammahboubmd budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT emilykutriebba budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai AT ahuvaaverinmpp budgetaryimpactof20valentpneumococcalconjugatevaccineuseforadultexpatriateslivingindubai |